Zymeworks (ZYME) Surges On Positive Ziihera Phase 3 Data In First-Line GEA (ZYME)

Zymeworks Inc. ( ZYME ), as of today, represents a pretty compelling clinical-stage biotech opportunity. Shares jumped as much as 30% today on the back of news that its bispecific HER2-targeted antibody Ziihera has demonstrated positive Phase 3 results in first-line HER2-positive gastroesophagealI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, ...